Literature DB >> 6528131

The evaluation of therapies: historical control studies.

E A Gehan.   

Abstract

Mesh：

Year:  1984        PMID： 6528131     DOI： 10.1002/sim.4780030405

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  10 in total

1.  No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Oliviero Riggio; Silvia Nardelli; Chiara Pasquale; Ilaria Pentassuglio; Stefania Gioia; Eugenia Onori; Camilla Frieri; Filippo Maria Salvatori; Manuela Merli
Journal:  Metab Brain Dis       Date:  2015-08-20       Impact factor: 3.584

2.  Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?

Authors:  Scott R Evans; John Powers
Journal:  Stat Commun Infect Dis       Date:  2017-03-14

Review 3.  Methods and issues in studies of CRE.

Authors:  Scott R Evans; Anthony D Harris
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

4.  Comment: Fundamentals and Innovation in Antibiotic Trials.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2015-12-17       Impact factor: 1.452

5.  Sample size considerations for historical control studies with survival outcomes.

Authors:  Hong Zhu; Song Zhang; Chul Ahn
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

6.  Design and analysis of a clinical trial using previous trials as historical control.

Authors:  David Alan Schoenfeld; Dianne M Finkelstein; Eric Macklin; Neta Zach; David L Ennist; Albert A Taylor; Nazem Atassi
Journal:  Clin Trials       Date:  2019-07-01       Impact factor: 2.486

7.  Treatment-subgroup interaction: an example from a published, phase II clinical trial.

Authors:  Carolyn E Behrendt; Edmund A Gehan
Journal:  Contemp Clin Trials       Date:  2009-02-21       Impact factor: 2.226

8.  Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.

Authors:  Nelson B Watts; Robert Lindsay; Zhengqing Li; Chandrasekhar Kasibhatla; Jacques Brown
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

Review 9.  Sample size: how many patients are necessary?

Authors:  P M Fayers; D Machin
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

Review 10.  A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG).

Authors:  Mercedeh Ghadessi; Rui Tang; Joey Zhou; Rong Liu; Chenkun Wang; Kiichiro Toyoizumi; Chaoqun Mei; Lixia Zhang; C Q Deng; Robert A Beckman
Journal:  Orphanet J Rare Dis       Date:  2020-03-12       Impact factor: 4.123
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.